|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
61,390,000 |
Market
Cap: |
422.36(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.15 - $24.1 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
12,568 |
159,192 |
218,988 |
Total Sell Value |
$0 |
$137,243 |
$3,016,052 |
$4,045,075 |
Total People Sold |
0 |
2 |
9 |
9 |
Total Sell Transactions |
0 |
2 |
17 |
25 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Love Colin |
Chief Operating Officer |
|
2019-11-06 |
4 |
AS |
$17.00 |
$382,725 |
D/D |
(22,500) |
1,051,524 |
|
- |
|
Coffin Robert |
President and CEO |
|
2019-11-06 |
4 |
AS |
$17.00 |
$824,985 |
D/D |
(48,500) |
2,266,618 |
|
- |
|
Coffin Robert |
President and CEO |
|
2019-11-04 |
4 |
AS |
$17.00 |
$825,761 |
D/D |
(48,500) |
2,315,118 |
|
- |
|
Love Colin |
Chief Operating Officer |
|
2019-11-04 |
4 |
AS |
$17.00 |
$383,085 |
D/D |
(22,500) |
1,074,024 |
|
- |
|
Astley-Sparke Philip |
Executive Chairman |
|
2019-11-04 |
4 |
AS |
$17.00 |
$493,754 |
D/D |
(29,000) |
1,384,297 |
|
- |
|
Love Colin |
Chief Operating Officer |
|
2019-10-31 |
4 |
AS |
$17.00 |
$191,250 |
D/D |
(11,250) |
1,096,524 |
|
- |
|
Coffin Robert |
President and CEO |
|
2019-10-31 |
4 |
AS |
$17.00 |
$412,250 |
D/D |
(24,250) |
2,363,618 |
|
- |
|
Astley-Sparke Philip |
Executive Chairman |
|
2019-10-31 |
4 |
AS |
$17.00 |
$246,500 |
D/D |
(14,500) |
1,413,297 |
|
- |
|
Atlas Venture Fund X, L.p. |
10% Owner |
|
2019-02-12 |
4 |
AS |
$0.00 |
$0 |
D/D |
(631,073) |
3,822,313 |
|
- |
|
Esposito Pamela |
Chief Business Officer |
|
2018-12-13 |
4 |
OE |
$1.75 |
$152,250 |
D/D |
87,000 |
87,000 |
|
- |
|
Koppel Adam |
Director |
|
2018-07-24 |
4 |
B |
$15.00 |
$7,500,000 |
I/I |
500,000 |
2,838,968 |
2.1 |
- |
|
Koppel Adam |
Director |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,338,968 |
2,338,968 |
|
- |
|
Forbion Capital Fund Iii Cooperatief U.a. |
10% Owner |
|
2018-07-24 |
4 |
B |
$15.00 |
$1,999,995 |
I/I |
133,333 |
4,721,449 |
1.5 |
- |
|
Forbion Capital Fund Iii Cooperatief U.a. |
10% Owner |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
4,588,116 |
4,588,116 |
|
- |
|
Slattery Joseph P |
Director |
|
2018-07-24 |
4 |
B |
$15.00 |
$100,005 |
D/D |
6,667 |
6,667 |
2.39 |
- |
|
Atlas Venture Associates X, L.p. |
10% Owner |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,453,386 |
4,453,386 |
|
- |
|
Rhodes Jason P |
Director |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
4,453,386 |
4,453,386 |
|
- |
|
Slootweg Hugo Alexander |
Director |
|
2018-07-24 |
4 |
B |
$15.00 |
$1,999,995 |
I/I |
133,333 |
4,721,449 |
2.25 |
- |
|
Slootweg Hugo Alexander |
Director |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
4,588,116 |
4,588,116 |
|
- |
|
Green Jeremy |
10% Owner |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
779,655 |
779,655 |
|
- |
|
Paster Anne-Mari |
10% Owner |
|
2018-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,588,116 |
4,854,783 |
|
- |
|
Paster Anne-Mari |
10% Owner |
|
2018-07-24 |
4 |
B |
$15.00 |
$4,000,005 |
D/D |
266,667 |
266,667 |
2.45 |
- |
|
172 Records found
|
|
Page 7 of 7 |
|
|